Table 3:
Additive therapy and follow-up
| Study population, n = 58 | |
|---|---|
| Induction chemotherapy, n (%) | 20 (34.5) |
| Adjuvant chemotherapy | 7 (12.1) |
| Additive chemotherapy | 25 (43.1) |
| Adjuvant radiotherapy | 13 (22.4) |
| Tumour recurrence (R0/1, n = 49) | 24 (48.9) |
| Tumour progression (R2, n = 9) | 7 (77.8) |
| Location of recurrence/progression (n = 31) | |
| Loco-regional | 24 (77.4) |
| Distant metastasis | 6 (19.4) |
| Both | 1 (3.2) |
| Side of recurrence/progression (n = 31) | |
| Ipsilateral | 29 (93.5) |
| Contralateral | 2 (6.5) |
| Therapy of recurrence/progression (n = 31) | |
| No | 3 (9.7) |
| Unknown | 2 (6.5) |
| Yes/type | 26 (83.9) |
| Surgery | 4 (15.4) |
| Chemotherapy | 13 (50.0) |
| Radiotherapy | 7 (26.9) |
| Best supportive care | 1 (3.8) |
| Other | 2 (7.7) |
| Time between start of primary therapy till follow-up end in months,a median (95% CI) | 59 (42–76) |
| Alive at the end of follow-up | 45 (77.5) |
a
Reverse Kaplan–Meier OS.
CI: confidence interval; OS: overall survival.